New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
11:10 EDTCYTK, CONN, INSM, EXAS, GALTOptions with decreasing implied volatility: GALT INSM CYTK EXAS CONN
News For GALT;INSM;CYTK;EXAS;CONN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
10:00 EDTEXASOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:56 EDTEXASExact Sciences upgraded to Buy from Hold at Lake Street
Lake Street Capital Markets analyst Bruce Jackson upgraded Exact Sciences to Buy and raised his price target for shares to $30 from $27. The company's Q2 report showed better than expected gross margins and the stock's risk/reward is appealing, Jackson tells investors.
July 21, 2015
09:21 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
09:13 EDTEXASExact Sciences 7M share Spot Secondary priced at $25.50
Subscribe for More Information
July 20, 2015
19:02 EDTEXASOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTEXASExact Sciences files to sell 7M shares of common stock
The Company intends to use the net proceeds of this offering to fund expansion of Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes. Jefferies LLC and Robert W. Baird & Co. Incorporated are acting as the underwriters for the offering.
09:22 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
05:32 EDTEXASExact Sciences reports Q2 EPS (44c), consensus (45c)
Reports Q2 revenue $8.1M, consensus $7.96M.
July 15, 2015
10:01 EDTCYTKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:59 EDTCYTKCytokinetics initiated with an Outperform at Cowen
Subscribe for More Information
July 14, 2015
11:10 EDTEXASExact Sciences management to meet with Jefferies
Subscribe for More Information
10:41 EDTCYTKCytokinetics awarded $1.5M grant for Phase 3 clinical trial, collaboration
Subscribe for More Information
07:38 EDTCYTKCytokinetics awarded $1.5M grant by ALS Association
Subscribe for More Information
07:37 EDTCYTKCytokinetics initiates Phase 3 clinical trial of tirasemtiv in ALS patients
Cytokinetics announced the start of VITALITY-ALS, or Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices after Treatment for a Year in ALS, a Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity, or SVC, and other measures of respiratory function in patients with ALS. VITALITY-ALS is a multi-national, randomized, double-blind, placebo-controlled trial that is designed to enroll 445 patients with possible, probable or definite ALS, diagnosed within 24 months, and with percent predicted SVC at baseline greater than or equal to 70%. Patients may be enrolled whether or not they are on riluzole therapy. The primary endpoint of the trial will assess change from baseline in SVC, to be assessed after 24 weeks of double-blind, placebo-controlled treatment. Secondary endpoints, to be assessed at 48 weeks, include time to decline in any of the three respiratory domains of the ALSFRS-R or death; time to decline from baseline in percent predicted SVC by greater than or equal to 20 percentage points or the onset of respiratory insufficiency or death; time to first occurrence of any use of assisted ventilation or death; time to decline from baseline in percent predicted SVC to less than or equal to 50% predicted or the onset of respiratory insufficiency or death; and change in the Mega-Score of muscle strength.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use